Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: last dosechildbearing potentialof childbearingpotential mustcontrol one
  Phrases that lowered it: the pharmacokineticsand safetysingle doseto evaluateevaluate the
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 16.7% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 981 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 142 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. NCT05329623 · started 2022 · scored riskier than 4% of active trials completed
• PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers NCT02121860 · started 2014 · scored riskier than 7% of active trials completed
• Effect of Hepatic Impairment on LDE225.. NCT01764776 · started 2013 · scored riskier than 4% of active trials completed
• Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) NCT00730431 · started 2008 · scored riskier than 5% of active trials completed
• Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects NCT03802786 · started 2018 · scored riskier than 2% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.